Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
VOLTAREN-XR is an extended-release oral tablet formulation of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). While specific indications are not listed in available data, diclofenac is typically used to treat pain and inflammation associated with conditions such as arthritis, musculoskeletal disorders, and postoperative pain. The drug works by inhibiting cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely transitioning toward lifecycle extension strategies and managing volume decline.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on VOLTAREN-XR offers limited growth opportunities given its LOE-approaching status and lack of linked job openings. Career value lies in gaining experience in lifecycle management, competitive positioning, and market access strategy in a mature product environment.
Worked on VOLTAREN-XR at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.